320420-00-6Relevant articles and documents
NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS
-
Page/Page column 64; 166, (2020/03/05)
The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds, methods of using the compounds and methods of determining the monoacylglycerol lipase (MAGL) inhibitory activity of the compounds.
NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS
-
Page/Page column 174, (2020/03/05)
The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
ARBOVIRUS INHIBITORS AND USES THEREOF
-
, (2012/10/08)
The present invention relates to chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides compounds as inhibitors of arboviruses.
A highly efficient Pd-C catalytic hydrogenation of pyridine nucleus under mild conditions
Cheng, Chuanjie,Xu, Jimin,Zhu, Rui,Xing, Lixin,Wang, Xinyan,Hu, Yuefei
supporting information; experimental part, p. 8538 - 8541 (2009/12/24)
A synergistic Pd-C catalytic hydrogenation of 4-pyridinecarboxamides straightforward to 4-piperidinecarboxamide hydrochlorides was developed in the presence of ClCH2CHCl2. It provided a novel strategy for highly efficient hydrogenati
1-{2-[(DIPHENYL)AMINO]-ETHYL}-PIPERIDINE-4-CARBOXYLIC ACID BENZYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS CCR5 AGONISTS FOR THE TREATMENT OF IMMUNE AND INFLAMMATORY DISEASES
-
Page/Page column 95, (2009/03/07)
The present invention relates to pharmaceutically active piperidine derivatives and their use as agonists of CC chemokine receptor activity, more specifically of CCR5 activity. Chemokines are chemotactic cytokines which play an important role in immune and inflammatory responses.